Fortress Biotech Inc. (NASDAQ: FBIO) is 29.18% higher on its value in year-to-date trading and has touched a low of $1.04 and a high of $3.45 in the current 52-week trading range. The FBIO stock was last observed hovering at around $3.05 in the last trading session, with the day’s gains setting it 0.27% off its average median price target of $6.00 for the next 12 months. It is also 82.53% off the consensus price target high of $19.00 offered by 5 analysts, but current levels are 26.22% higher than the price target low of $4.50 for the same period.
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
Currently trading at $3.32, the stock is 15.45% and 16.57% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.65 million and changing 8.85% at the moment leaves the stock 44.83% off its SMA200. FBIO registered 147.76% gain for a year compared to 6-month gain of 28.68%. The firm has a 50-day simple moving average (SMA 50) of $1.97% and a 200-day simple moving average (SMA200) of $539k.
The stock witnessed a 22.51% loss in the last 1 month and extending the period to 3 months gives it a 25.76%, and is 14.48% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.87% over the week and 8.33% over the month.
Fortress Biotech Inc. (FBIO) has around 93 employees, a market worth around $263.97M and $43.10M in sales. Distance from 52-week low is 219.23% and -3.77% from its 52-week high. The company has generated returns on investments over the last 12 months (-79.70%).
Fortress Biotech Inc. (FBIO) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Fortress Biotech Inc. (FBIO) is a “Buy”. 5 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Fortress Biotech Inc. is expected to release its quarterly report on 11/06/2020 and quarterly earnings per share for the current quarter are estimated at -$0.27 with sales reaching $11.03M over the same period.The EPS is expected to grow by 56.50% this year, but quarterly earnings will post 35.40% year-over-year. Quarterly sales are estimated to grow 46.90% in year-over-year returns.
Fortress Biotech Inc. (FBIO) Top Institutional Holders
67 institutions hold shares in Fortress Biotech Inc. (FBIO), with 23.2M shares held by insiders accounting for 28.13% while institutional investors hold 19.60% of the company’s shares. The shares outstanding are 63.50M, and float is at 60.05M with Short Float at 2.70%. Institutions hold 14.09% of the Float.
Fortress Biotech Inc. (FBIO) Insider Activity
A total of 0 insider transactions have happened at Fortress Biotech Inc. (FBIO) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider purchase by ROSENWALD LINDSAY A MD, the company’s PRESIDENT, CEO & CHAIRMAN. SEC filings show that ROSENWALD LINDSAY A MD bought 1,123 shares of the company’s common stock on Dec 01 at a price of $2.06 per share for a total of $2313.0. Following the purchase, the insider now owns 8.57 million shares.
Fortress Biotech Inc. (FBIO): Who are the competitors?
The company’s main competitors (and peers) include Biogen Inc. (BIIB) that is trading 27.34% up over the past 12 months. Sanofi (SNY) is 22.47% up on the 1-year trading charts.